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Abstract
Background:  Kappa is commonly used when assessing the agreement of conditions with
reference standard, but has been criticized for being highly dependent on the prevalence. To
overcome this limitation, a prevalence-adjusted and bias-adjusted kappa (PABAK) has been
developed. The purpose of this study is to demonstrate the performance of Kappa and PABAK,
and assess the agreement between hospital discharge administrative data and chart review data
conditions.
Methods: The agreement was compared for random sampling, restricted sampling by conditions,
and case-control sampling from the four teaching hospitals in Alberta, Canada from ICD10
administrative data during January 1, 2003 and June 30, 2003. A total of 4,008 hospital discharge
records and chart view, linked for personal unique identifier and admission date, for 32 conditions
of random sampling were analyzed. The restricted sample for hypertension, myocardial infarction
and congestive heart failure, and case-control sample for those three conditions were extracted
from random sample. The prevalence, kappa, PABAK, positive agreement, negative agreement for
the condition was compared for each of three samples.
Results: The prevalence of each condition was highly dependent on the sampling method, and this
variation in prevalence had a significant effect on both kappa and PABAK. PABAK values were
obviously high for certain conditions with low kappa values. The gap between these two statistical
values for the same condition narrowed as the prevalence of the condition approached 50%.
Conclusion: Kappa values varied more widely than PABAK values across the 32 conditions.
PABAK values should usually not be interpreted as measuring the same agreement as kappa in
administrative data, particular for the condition with low prevalence. There is no single statistic
measuring agreement that captures the desired information for validity of administrative data.
Researchers should report kappa, the prevalence, positive agreement, negative agreement, and the
relative frequency in each cell (i.e. a, b, c and d) to enable the reader to judge the validity of
administrative data from multiple aspects.
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Background
Measuring validity, including content, construction, and
criterion validity is a fundamental issue for medical
research. In epidemiological studies, criterion validity
(referred to simply as validity in this paper), is most
widely used, and depends heavily on the criterion meas-
urement. Ideally, the criterion should completely reflect
the 'truth', and is commonly referred to as the 'gold stand-
ard'. Upon implementation of the 'gold standard', statis-
tics of sensitivity, specificity, positive predictive value
(PPV) and negative predictive value (NPV) are employed
to quantify the validity of a measure that is being exam-
ined.
In the 'real' world, particularly in epidemiological studies,
a 'gold standard' is rarely available, too difficult, or costly
to establish. Therefore researchers often utilize proximate
measures of the 'gold standard' as the criterion to assess
validity. For example, the validity of medical conditions
recorded in hospital discharge administrative data has
been assessed by re-abstraction of inpatient charts by
health professionals, as well as comparison with patient
self-reported data. In these situations when there is no
'gold standard', the kappa statistic is commonly used to
assess agreement for estimating "validity".
In 1960, based on the chance-corrected reliability of con-
tent analysis[1], Cohen developed the kappa statistic for
evaluation of categorical data, which corrects or adjusts
for the amount of agreement that can be expected to occur
by chance alone[2]. Since its inception, kappa has been
widely studied and critiqued (Table 1). One common crit-
icism is that kappa is highly dependent on the prevalence
of the condition in the population[3,4]. To overcome this
limitation, several alternative methods for agreement
have been investigated [5-8]. In 1993, Byrt et al[9] pro-
posed a bias-adjusted and prevalence-adjusted kappa
(PABAK) that assumes fifty percent prevalence of the con-
dition, and absence of any bias. PABAK has been
employed in many pervious studies for agreement assess-
ment [10-17]. Compared with kappa, PABAK reflects the
ideal situation, and ignores the variation of prevalence
across the conditions and bias presented in the "real"
world. To demonstrate the performance of kappa and
PABAK, we assessed the agreement between hospital dis-
charge administrative data and chart review data condi-
tions, considering that the prevalence of a condition
varies by the sampling method employed. We analyzed
kappa and PABAK in the following three sampling scenar-
ios; 1) random sampling, 2) restricted sampling by condi-
tions, and 3) case-control sampling.
Methods
Random sample
A total of 4,008 hospital discharge records were randomly
selected from the four adult teaching hospitals in Alberta,
Canada among admissions during January 1, 2003 and
June 30, 2003. There were at least 1000 records from each
hospital.
Defining conditions in ICD-10 administrative data
Professional trained health record coders read through the
patient' medical chart to assign International Classifica-
tion of Disease 10th  version (ICD-10) diagnoses that
appropriately described the patient's hospitalization.
Each discharge record contained a unique identification
number for each admission, a patient chart number, and
up to 16 diagnoses. We defined 32 conditions based on
ICD-10 codes[18].
Defining conditions in chart data
Charts of the randomly selected 4008 patients were
located using the personal unique identifier and admis-
sion date. Two professionally trained reviewers completed
a thorough chart review of 4008 patients through examin-
ing the chart cover page, discharge summaries, narrative
summaries, pathology reports (including autopsy
reports), trauma and resuscitation records, admission
Table 1: Literature related to kappa
Author Main contribution
Cohen[2] Investigate chance-corrected kappa agreement coefficient and its standard error, techniques for estimation, 
and hypothesis testing
Cohen[27] Provide weighted version of kappa for ordinal statistics
Fleiss et al[28] Investigate asymptotic variance formula for testing kappa and CI of kappa for general m × m table
Landis et al[29] Provide arbitrarily the range of kappa value to the degree of agreement
Fleiss[30], Landis et al[31] Extended kappa for more than 2 raters, and multiple categories
Bloch et al[5] Investigate intraclass kappa and its CI estimation
Cicchetti et al[3], Feinstein et al[4] Investigate the effect of bias and prevalence on kappa
Barlow[32] Investigate kappa statistics included covariates
Oden et al[33] Extended the kappa for paired-data
Byrt et al[9] Introduced prevalence-adjusted bias-adjusted kappa
Vach[22] The effects of prevalence and bias on kappa is negligibleBMC Medical Research Methodology 2009, 9:5 http://www.biomedcentral.com/1471-2288/9/5
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notes, consultation reports, surgery/operative reports,
anesthesia reports, physician daily progress notes, physi-
cian orders, diagnostic reports, and transfer notes for evi-
dence of any of the 32 conditions. The process took
approximately one hour for each chart.
Restricted sample
We extracted records with any one of three conditions (i.e.
hypertension, myocardial infarction and congestive heart
failure) from the ICD-10 administrative data. Among
1126 records that met the criteria, there were 887 records
with hypertension, 336 with myocardial infarction and
254 with congestive heart failure.
Case-control sample
We defined a case-control sample for each of the three
specific conditions based on ICD-10 administrative data.
The first sample included 887 records with hypertension
and 887 randomly selected records among those without
hypertension. Thus in total the sample for hypertension
contained 1774 records. Using the same method, the sec-
ond and third sample was generated for myocardial inf-
arction and congestive heart failure. In total there were
672 records for myocardial infarction (336 with myocar-
dial infarction, 336 without) and 508 records for conges-
tive heart failure (254 with congestive heart failure and
254 records without).
Statistical indices of agreement
We calculated the prevalence of condition, kappa, PABAK
statistic, positive agreement, negative agreement,
observed agreement, and chance agreement for the condi-
tion in each of three samples. The definition of kappa and
PABAK is:
Where Io and Ie is observed agreement and chance agree-
ment, respectively.
The cross-classification for the results of the condition by
two databases and the formulas for calculating agreement
statistics can be found in Additional file 1. We calculated
statistical values in the three samples, such as kappa.
These refer to statistics for samples and do not refer to
parameter values for populations although the sample
statistics are used to estimate population values. There-
fore, the statistical indices used in this paper refer to the
statistical value for sample, not for population.
This study was approved by the ethics committee of Uni-
versity of Calgary, Canada
Results
Random sample for 32 conditions
The statistical indices for agreement for the 32 conditions
are presented in table 2. The prevalence of the conditions
for ICD-10 administrative data ranged from 0.25% to
22.13%, whereas for chart review, it was from 0.60% to
30.19% among the 32 conditions. The variation for nega-
tive agreement was from 0.92 to 1.00, and from 0.21 to
0.84 for positive agreement. The kappa varied from 0.20
to 0.83, whereas for PABAK, it was from 0.72 to 0.99, with
the PABAK value greater than kappa for all conditions in
the sample. The difference between PABAK and kappa val-
ues ranged from 0.06 to 0.77. Hypertension and meta-
static cancer had the lowest difference of 0.06, while
blood loss anemia and coagulopathy had the most
extreme difference of 0.77. The kappa and PABAK with the
prevalence of 32 conditions illustrate in the figure 1.
Restricted sample for select conditions
The prevalence of hypertension, myocardial infarction
and congestive heart failure for ICD-10 data increased
from 22.13%, 8.38%, 6.34% in the randomly selected
sample to 78.77%, 29.84% and 22.56% for restricted
sample, respectively (see Table 3). The difference between
PABAK and kappa values for hypertension, myocardial
infarction and congestive heart failure was 0.09, 0.03 and
0.05, respectively that changed from 0.06, 0.18 and 0.18
for the random sample.
Case-control sample for select conditions
By design the prevalence for these three conditions for
ICD-10 administrative data was 50%, both PABAK and
kappa values for hypertension, myocardial infarction and
congestive heart failure were 0.82, 0.88, and 0.89, result-
ing in a difference of 0 between these two indices.
Discussion
We investigated the performance of prevalence unad-
justed (i.e. kappa) and adjusted statistical indices (i.e.
PABAK) to assess agreement between administrative data
and medical chart review data in a randomly selected sam-
ple for 32 conditions, as well as a restricted, and case-con-
trol sample for three select conditions (hypertension,
myocardial infarction and congestive heart failure). Our
results indicate that for the same condition the prevalence
varies depending on the sampling method, and this vari-
ation affects both the kappa and PABAK statistic. We high-
light that 1) kappa values varied more widely than PABAK
values across the 32 conditions; 2) PABAK should usually
not be interpreted as measuring the same agreement
parameter as kappa in administrative data, particular for
the condition with low prevalence; 3) the gap between
these two statistical values for the same condition became
narrowed with an increase of its prevalence and disap-
peared when the prevalence was fixed to 50%.
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Table 2: Prevalence and reliability index between chart abstract and ICD-10 discharge abstract data for 32 conditions
Chart (+) % p1 ICD10 (+) % p2 Chart(+) 
ICD10(+) %,(a)
Chart(-) ICD10(+) 
%,(b)
Chart(+) ICD10(-) 
%,(c)
Chart(-) ICD10(-) 
%, (d)
PABAK Kappa Positive 
agreement
Negative 
agreement
Hypertension 30.19 22.13 20.61 1.52 9.58 68.29 0.78 0.72 0.79 0.92
Diabetes without 
complication
11.88 10.18 9.01 1.17 2.87 86.95 0.92 0.79 0.82 0.98
Cardiac arrhythmias 21.80 9.10 8.50 0.60 13.30 77.60 0.72 0.48 0.55 0.92
Chronic pulmonary 
disease
15.00 8.71 7.91 0.80 7.09 84.21 0.84 0.63 0.67 0.96
Myocardial infarction 12.75 8.38 7.83 0.55 4.92 86.70 0.89 0.71 0.74 0.97
Solid tumor without 
metastasis
9.51 7.44 4.37 3.07 5.14 87.43 0.84 0.47 0.52 0.96
Congestive heart 
failure
8.33 6.34 5.71 0.62 2.62 91.04 0.94 0.76 0.78 0.98
Depression 11.90 5.84 5.34 0.50 6.56 87.60 0.86 0.57 0.60 0.96
Fluid and electrolyte 
disorders
11.05 5.61 4.02 1.60 7.04 87.35 0.83 0.44 0.48 0.95
Renal failure 3.99 4.89 3.14 1.75 0.85 94.26 0.95 0.69 0.71 0.99
Alcohol abuse 7.36 4.59 3.84 0.75 3.52 91.89 0.91 0.62 0.64 0.98
Cerebrovascular 
disease
8.13 4.54 3.77 0.77 4.37 91.09 0.90 0.57 0.59 0.97
Metastatic cancer 4.42 4.12 3.57 0.55 0.85 95.03 0.97 0.83 0.84 0.99
Hypothyroidism 8.83 3.72 3.47 0.25 5.36 90.92 0.89 0.53 0.55 0.97
Valvular disease 6.96 3.54 2.84 0.70 4.12 92.34 0.90 0.52 0.54 0.97
Drug abuse 4.92 2.82 2.30 0.52 2.62 94.56 0.94 0.58 0.59 0.98
Peripheral vascular 
disease
4.27 2.82 1.85 0.97 2.42 94.76 0.93 0.51 0.52 0.98
Diabetes with 
complication
2.74 2.57 1.62 0.95 1.12 96.31 0.96 0.60 0.61 0.99
Dementia 3.32 2.40 2.22 0.17 1.10 96.51 0.97 0.77 0.78 0.99
Liver disease 5.04 2.40 2.05 0.35 2.99 94.61 0.93 0.54 0.55 0.98
Obesity 8.31 1.85 1.55 0.30 6.76 91.39 0.86 0.28 0.30 0.96
Psychoses 2.89 1.82 1.65 0.17 1.25 96.93 0.97 0.69 0.70 0.99
Coagulopathy 7.71 1.80 1.07 0.72 6.64 91.57 0.85 0.20 0.23 0.96
Pulmonary circulation 
disorders
2.69 1.62 1.00 0.62 1.70 96.68 0.95 0.45 0.46 0.99
Rheumatic disease 2.59 1.42 1.37 0.05 1.22 97.36 0.97 0.68 0.68 0.99
Deficiency anemia 1.90 1.42 0.57 0.85 1.32 97.26 0.96 0.34 0.35 0.99
Hemiplegia or 
paraplegia
1.55 1.40 0.82 0.57 0.72 97.88 0.97 0.55 0.56 0.99
Peptic ulcer disease 2.52 1.30 1.00 0.30 1.52 97.18 0.96 0.52 0.52 0.99
Weight loss 3.74 0.85 0.47 0.37 3.27 95.88 0.93 0.19 0.21 0.98
Lymphoma 1.02 0.82 0.65 0.17 0.37 98.80 0.99 0.70 0.70 1.00
Blood loss anemia 1.12 0.62 0.20 0.42 0.92 98.45 0.97 0.22 0.23 0.99
AIDS/HIV 0.60 0.25 0.25 0.00 0.35 99.40 0.99 0.59 0.59 1.00BMC Medical Research Methodology 2009, 9:5 http://www.biomedcentral.com/1471-2288/9/5
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The sampling method employed has a significant effect
on the assessment of validity. Currently, random sample,
restricted sample, and case-control sample are popularly
used in validity study for administrative data [19-21]. In
our study, the kappa value for hypertension is 0.72 for
random sample and 0.69 for restricted sample. Previous
studies indicate that kappa value is highly dependent on
the prevalence of the condition[3,4]. The prevalence of
hypertension is 22.13% for the random sample and
78.77% for the restricted sample in this study. Therefore,
the difference of kappa value for hypertension might be
caused by the different prevalence between random and
restricted samples. The sampling method also impacted
the PABAK value, with the PABAK value varying by type of
sampling method. By definition the PABAK assumes the
prevalence is 50% with zero bias[6]; its value only
depends on the observed agreement[9]. It reaches to 0.82
for case-control sample when prevalence of hypertension
is 50%. These findings are consistent with Vach's[22]
report based on the hypothetical sample. In order to over-
come the effect of prevalence on kappa value, some
researchers advocate using a balance sample and avoiding
kappa to assess validity of conditions with low or very
high prevalence [3,4,9,23]. A potential reason for the var-
iation in PABAK by sampling methods is due to the
change in observed agreement, which was a result of the
variation in prevalence estimates by sampling methods.
Interpretation of validation study results should therefore
consider sampling effect and the disease prevalence.
Kappa is sensitive to the prevalence of a condition defined
from administrative data. Agresti's study[24] investigated
the influence of prevalence on kappa, and compared the
kappa values from populations with different prevalence.
Vach's[22] study indicated the kappa is highest when
prevalence equals 50%. In reality, nearly all diseases have
prevalence lower than 50% in populations. Case-control
study design (1:1 matching) automatically maximizes
kappa value. In our study, kappa for hypertension in the
case-control sample of 0.82 was higher than that in the
random sample of 0.72. Therefore, caution should be
used in interpreting kappa for case-control studies.
In this study, we compared performance of kappa and
PABAK in measuring agreement between administrative
data and chart review data but were unable to determine
which statistic measures agreement more accurately and
reliably. The reason is that we could not establish param-
eter of 'true' validity of administrative data. However,
assessment of these two statistics through administrative
data coding practice (i.e. face-validity) demonstrates that
PABAK values should usually not be interpreted as meas-
The comparison of kappa and PABAK with changes of the prevalence of the conditions Figure 1
The comparison of kappa and PABAK with changes of the prevalence of the conditions.
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Table 3: Prevalence and reliability index between chart abstract and ICD-10 discharge abstract data for 3 select conditions, by sampling method
Chart (+)
p1, %
ICD10 (+)
p2,%
Chart(+)
ICD10(+)
(a),%
Chart(-)
ICD10(+)
(b),%
Chart(+)
ICD10(-) (c),
%
Chart(-)
ICD10(-)
(d),%
Positive
agreement
Negative
agreement
PABAK Kappa (PABAK-
kappa)
Observed
agreement
(Io)
Chance
agreement
(Ie)
Random 
sample
Hypertensi
on
30.19 22.13 20.61 1.52 9.58 68.29 0.79 0.92 0.78 0.72 0.06 0.89 0.61
Myocardial 
infarction
12.75 8.38 7.83 0.55 4.92 86.70 0.74 0.97 0.89 0.71 0.18 0.95 0.81
Congestive 
heart 
failure
8.33 6.34 5.71 0.62 2.62 91.04 0.78 0.98 0.94 0.76 0.18 0.97 0.86
Restricted 
sample#
Hypertensi
on
78.51 78.77 73.36 5.42 5.15 16.07 0.93 0.75 0.78 0.69 0.09 0.89 0.66
Myocardial 
infarction
37.92 29.84 27.89 1.95 10.04 60.12 0.82 0.91 0.76 0.73 0.03 0.88 0.55
Congestive 
heart 
failure
25.58 22.56 20.34 2.22 5.24 72.20 0.85 0.95 0.85 0.80 0.05 0.93 0.63
Case-control 
sample$
Hypertensi
on
52.20 50.00 46.56 3.44 5.64 44.36 0.91 0.91 0.82 0.82 0.00 0.91 0.50
Myocardial 
infarction
49.70 50.00 46.73 3.27 2.98 47.02 0.94 0.94 0.88 0.88 0.00 0.94 0.50
Congestive 
heart 
failure
45.47 50.00 45.08 4.92 0.39 49.61 0.94 0.95 0.89 0.89 0.00 0.95 0.50
#: The sample restricted to the condition of hypertension, myocardial infarction, and congestive heart failure
$: Condition chosen first, with random selection of controls without the condition of interest.BMC Medical Research Methodology 2009, 9:5 http://www.biomedcentral.com/1471-2288/9/5
Page 7 of 8
(page number not for citation purposes)
uring the same agreement parameter as kappa, particular
for the condition with low prevalence. In our random
sample, PABAK value ranged from 0.72 to 0.99 among 32
conditions, indicating a high degree of "validity" for
administrative data in recording these conditions. The
high PABAK value for obesity and weight loss are exam-
ples (0.96 for both conditions) that question the PABAK
validity. Administrative data coding guideline and prac-
tice[25] instructs coders not to code these conditions even
if they are documented in charts because they may not
affect length of stay, healthcare or therapeutic treatment.
Additionally, coders may intentionally not code these
conditions due to the limited amount of time given to
code each chart. Therefore, these two conditions generally
have very poor validity in administrative data. The fact is
revealed by the very poor positive agreement (0.30 for
obesity and 0.21 for weight loss, respectively) and kappa
value (0.20 and 0.28). PABAK assumes the bias is absent
and the prevalence is 50%. However, when bias presented
and the prevalence departed from 50%, the PABAK value
and kappa value are inconsistence.
Bias also has an effect on the kappa values. Bias is the
extent to which there is disagreement on the proportion of
positive (or negative) cases and is reflected in a difference
between b and c (see Additional file 1)[26]. The kappa
value is higher for a large bias, while the kappa value is
lower for lower or absent bias[9]. In our study, the value
of b and c changed for the same condition in the different
samples. For myocardial infarction, the value of b and c
was 0.55% and 4.92% in the random sample, respec-
tively, whereas it was 1.95% and 10.04% in the restricted
sample. Furthermore, the prevalence of the condition also
changed from 8.38% for random sample, and 29.84% for
restricted sample, respectively. According to the definition
of kappa, it is obvious that the changes of prevalence have
the effect on kappa. For the restricted sample, both the dif-
ference of b and c, and the prevalence of myocardial inf-
arction are higher compared to the random sample. This
partly explains why the kappa value is higher in the
restricted sample than those in the random sample.
Our study at least has two limitations. Firstly, we cannot
capture the 'true' value of the kappa for the conditions in
the administrative data in our study. Therefore, the differ-
ence between the 'true' value and estimated value of
kappa, and their changes due to the variation of preva-
lence, cannot be evaluated. Secondly, we employed chart
data extracted by reviewers as a 'gold standard' to assess
the validity of ICD-10 data. Such a criterion standard
depends on the quality of charts.
Conclusion
Our study indicates the prevalence of conditions varies
depending on the sampling method employed, and these
changes have an effect on kappa and PABAK. Although
PABAK theoretically adjusts for prevalence, this statistic
may be high to evaluate the agreements between two data
sources, and may result in misleading conclusion.
Although no single agreement statistic can capture the
desired information, we encourage researchers to report
kappa, the prevalence, positive agreement, negative agree-
ment, and the relative frequency of in each cell (i.e. a, b, c
and d) to permit readers to judge the validity of adminis-
trative data from multiple aspects.
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